We begin with an interview with Dr. William A. Wood of the University of North Carolina, Chapel Hill. Dr. Wood is current Chair of the ASH Research Collaborative's Data Hub Oversight Group, and he spoke with us about the new COVID-19 Registry for Malignant Hematology. Next, we'll move onto a report on the relationship between breastfeeding and reduced risk of invasive ovarian cancer. And to round out this week's episode, we'll go over the FDA's approval of lustpatercept-aamt for anemia in patients with myelodysplastic syndromes.

Coverage of stories discussed this week on ascopost.com:

ASH Research Collaborative's Data Hub Creates International Data Registry for Patients With Blood Cancers and COVID-19

Does Breastfeeding Affect Invasive Ovarian Cancer Risk?

FDA Approves Luspatercept-aamt for Second-Line Treatment of Anemia in Adult Patients With Myelodysplastic Syndromes

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> We begin with an interview with Dr. William A. Wood of the University of North Carolina, Chapel Hill. Dr. Wood is current Chair of the ASH Research Collaborative's Data Hub Oversight Group, and he spoke with us about the new COVID-19 Registry for Malignant Hematology. Next, we'll move onto a report on the relationship between breastfeeding and reduced risk of invasive ovarian cancer. And to round out this week's episode, we'll go over the FDA's approval of lustpatercept-aamt for anemia in patients with myelodysplastic syndromes.

We begin with an interview with Dr. William A. Wood of the University of North Carolina, Chapel Hill. Dr. Wood is current Chair of the ASH Research Collaborative's Data Hub Oversight Group, and he spoke with us about the new COVID-19 Registry for Malignant Hematology. Next, we'll move onto a report on the relationship between breastfeeding and reduced risk of invasive ovarian cancer. And to round out this week's episode, we'll go over the FDA's approval of lustpatercept-aamt for anemia in patients with myelodysplastic syndromes.

Coverage of stories discussed this week on ascopost.com:

ASH Research Collaborative's Data Hub Creates International Data Registry for Patients With Blood Cancers and COVID-19

Does Breastfeeding Affect Invasive Ovarian Cancer Risk?

FDA Approves Luspatercept-aamt for Second-Line Treatment of Anemia in Adult Patients With Myelodysplastic Syndromes

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:

We begin with an interview with Dr. William A. Wood of the University of North Carolina, Chapel Hill. Dr. Wood is current Chair of the ASH Research Collaborative's Data Hub Oversight Group, and he spoke with us about the new COVID-19 Registry for Malignant Hematology. Next, we'll move onto a report on the relationship between breastfeeding and reduced risk of invasive ovarian cancer. And to round out this week's episode, we'll go over the FDA's approval of lustpatercept-aamt for anemia in patients with myelodysplastic syndromes.

Coverage of stories discussed this week on ascopost.com:

ASH Research Collaborative's Data Hub Creates International Data Registry for Patients With Blood Cancers and COVID-19

Does Breastfeeding Affect Invasive Ovarian Cancer Risk?

FDA Approves Luspatercept-aamt for Second-Line Treatment of Anemia in Adult Patients With Myelodysplastic Syndromes

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> ASH Research Collaborative's Data Hub Creates International Data Registry for Patients With Blood Cancers and COVID-19

We begin with an interview with Dr. William A. Wood of the University of North Carolina, Chapel Hill. Dr. Wood is current Chair of the ASH Research Collaborative's Data Hub Oversight Group, and he spoke with us about the new COVID-19 Registry for Malignant Hematology. Next, we'll move onto a report on the relationship between breastfeeding and reduced risk of invasive ovarian cancer. And to round out this week's episode, we'll go over the FDA's approval of lustpatercept-aamt for anemia in patients with myelodysplastic syndromes.

Coverage of stories discussed this week on ascopost.com:

ASH Research Collaborative's Data Hub Creates International Data Registry for Patients With Blood Cancers and COVID-19

Does Breastfeeding Affect Invasive Ovarian Cancer Risk?

FDA Approves Luspatercept-aamt for Second-Line Treatment of Anemia in Adult Patients With Myelodysplastic Syndromes

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Does Breastfeeding Affect Invasive Ovarian Cancer Risk?

We begin with an interview with Dr. William A. Wood of the University of North Carolina, Chapel Hill. Dr. Wood is current Chair of the ASH Research Collaborative's Data Hub Oversight Group, and he spoke with us about the new COVID-19 Registry for Malignant Hematology. Next, we'll move onto a report on the relationship between breastfeeding and reduced risk of invasive ovarian cancer. And to round out this week's episode, we'll go over the FDA's approval of lustpatercept-aamt for anemia in patients with myelodysplastic syndromes.

Coverage of stories discussed this week on ascopost.com:

ASH Research Collaborative's Data Hub Creates International Data Registry for Patients With Blood Cancers and COVID-19

Does Breastfeeding Affect Invasive Ovarian Cancer Risk?

FDA Approves Luspatercept-aamt for Second-Line Treatment of Anemia in Adult Patients With Myelodysplastic Syndromes

"}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Luspatercept-aamt for Second-Line Treatment of Anemia in Adult Patients With Myelodysplastic Syndromes